{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:10:44Z","timestamp":1790075444635,"version":"4.0.1"},"reference-count":30,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,7,10]]},"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Surgery is one of the treatments of choice for patients with a single metastasis from melanoma but is rarely curative. Such patients could potentially benefit from consolidation immunotherapy. Vaccination with dendritic cells (DCs) loaded with tumour antigens elicits a tumour-specific immune response. In our experience, patients who developed delayed type hypersensitivity (DTH) after DC vaccination showed a median overall survival (OS) of 22.9 monthsvs4.8 months for DTH-negative cases. A phase II randomised trial showed an advantage OS of a DC vaccine over a tumour cell-based vaccine (2-year OS 72% vs31%, respectively). Given that there is no standard therapy after surgical resection of single metastases, we planned a study to compare vaccination with DCs pulsed with autologous tumour lysate versus follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>This is a randomised phase II trial in patients with resected stage III\/IV melanoma. Assuming a median relapse-free survival (RFS) of 7.0 months for the standard group and 11.7 months for the experimental arm (HR 0.60), with a two-sided tailed alpha of 0.10, 60 patients per arm must be recruited. An interim futility analysis will be performed at 18 months. The DC vaccine, produced in accordance with Good Manufacturing Practice guidelines, consists of autologous DCs loaded with autologous tumour lysate and injected intradermally near lymph nodes. Vaccine doses will be administered every 4 weeks for six vaccinations and will be followed by 3 million unit \/day of interleukin-2 for 5 days. Tumour restaging, blood sampling for immunological biomarkers and DTH testing will be performed every 12 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The protocol, informed consent and accompanying material given to patients were submitted by the investigator to the Ethics Committee for review. The local Ethics Committee and the Italian Medicines Agency approved the protocol (EudraCT code no.2014-005123-27). Results will be published in a peer-reviewed international scientific journal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>2014-005123-27.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2018-021701","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T05:55:51Z","timestamp":1533534951000},"page":"e021701","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)"],"prefix":"10.1136","volume":"8","author":[{"given":"Laura","family":"Ridolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"de Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fiammenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Granato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ancarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pancisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Soldati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Cassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Bulgarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Riccobon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gentili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Framarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tauceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Guidoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,8,5]]},"reference":[{"key":"2024051712422325000_8.8.e021701.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"2024051712422325000_8.8.e021701.2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.139.9.961"},{"key":"2024051712422325000_8.8.e021701.3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26111"},{"key":"2024051712422325000_8.8.e021701.4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2398-z"},{"key":"2024051712422325000_8.8.e021701.5","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21903"},{"key":"2024051712422325000_8.8.e021701.6","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.163"},{"key":"2024051712422325000_8.8.e021701.7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","article-title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016","volume":"63","author":"Garbe","year":"2016","journal-title":"Eur J Cancer"},{"key":"2024051712422325000_8.8.e021701.8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers8010017","article-title":"Updates in Therapy for Advanced Melanoma","volume":"8","author":"Singh","year":"2016","journal-title":"Cancers"},{"key":"2024051712422325000_8.8.e021701.9","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-012-2399-y","article-title":"Surgery for distant metastatic melanoma improves survival","volume":"19","author":"Kroon","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2024051712422325000_8.8.e021701.10","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040630"},{"key":"2024051712422325000_8.8.e021701.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1399"},{"key":"2024051712422325000_8.8.e021701.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)90001-7"},{"key":"2024051712422325000_8.8.e021701.13","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.482207"},{"key":"2024051712422325000_8.8.e021701.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1171-7"},{"key":"2024051712422325000_8.8.e021701.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-328"},{"key":"2024051712422325000_8.8.e021701.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0568-4"},{"key":"2024051712422325000_8.8.e021701.17","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3892\/or.2012.1956","article-title":"Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial","volume":"28","author":"Oshita","year":"2012","journal-title":"Oncol Rep"},{"key":"2024051712422325000_8.8.e021701.18","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32834b58fa"},{"key":"2024051712422325000_8.8.e021701.19","first-page":"670","article-title":"DC vaccination concurrently reduces Treg and anhances activated CTL in tumor biopsies from immunoresponsive patients with advanced melanoma. Abstract for the 26th annual scientific meeting of the society for immunotherapy of cancer [abstract]","volume":"34","author":"Guidoboni","year":"2011","journal-title":"J Immunotherapy"},{"key":"2024051712422325000_8.8.e021701.20","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-135"},{"key":"2024051712422325000_8.8.e021701.21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/CMR.0000000000000356","article-title":"Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience","volume":"27","author":"de Rosa","year":"2017","journal-title":"Melanoma Res"},{"key":"2024051712422325000_8.8.e021701.22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/CJI.0b013e31826f79c8","article-title":"Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma","volume":"35","author":"Dillman","year":"2012","journal-title":"J Immunother"},{"key":"2024051712422325000_8.8.e021701.23","first-page":"187","article-title":"Dendritic versus tumor cell presentation of autologous tumor antigens for active specific immunotherapy in metastatic melanoma: impact on long-term survival by extent of disease at the time of treatment","volume":"30","author":"Dillman","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"2024051712422325000_8.8.e021701.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.151"},{"key":"2024051712422325000_8.8.e021701.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.0500"},{"key":"2024051712422325000_8.8.e021701.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61033-8"},{"key":"2024051712422325000_8.8.e021701.27","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"},{"key":"2024051712422325000_8.8.e021701.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1103-3"},{"key":"2024051712422325000_8.8.e021701.29","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"2024051712422325000_8.8.e021701.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-021701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:01:53Z","timestamp":1715983313000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-021701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,5]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/bmjopen-2018-021701"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-021701","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}